What has PET told us about Parkinson's disease?

Area of Science:

• Neuroscience
• Medical Imaging
• Pharmacology

Background:

• Parkinson's disease (PD) is a neurodegenerative disorder affecting dopamine pathways.
• Positron emission tomography (PET) has been instrumental in visualizing the brain's dopaminergic system since 1983.
• Over 120 PET studies on PD have been documented in MEDLINE.

Purpose of the Study:

• To review the contributions of PET imaging to understanding Parkinson's disease.
• To highlight how PET reveals dopaminergic system alterations in PD.
• To discuss the utility of various radiotracers in PD research.

Main Methods:

• Utilizing 18F-fluorodopa to demonstrate presynaptic dopamine insufficiency.
• Employing 11C-nomifensine to visualize dopamine reuptake sites.
• Using radiolabeled D2-agonists and 11C-selegiline to assess receptor binding and enzyme inhibition.
• Applying 11C-L-dopa and PET to study L-dopa metabolism and dopamine concentration.

Main Results:

• PET with 18F-fluorodopa shows presynaptic dopamine deficiency in PD.
• Striatal dopaminergic terminals appear relatively preserved compared to post-mortem data.
• D2-agonist binding sites show a slight increase in early PD and no significant reduction in advanced stages.
• 11C-selegiline confirms MAO-B inhibition by therapeutic doses.
• 11C-L-dopa PET demonstrates rapid L-dopa decarboxylation and estimates dopamine levels related to 'on-response'.

Conclusions:

• PET imaging provides crucial insights into the dopaminergic system in Parkinson's disease.
• Different PET tracers offer valuable information on presynaptic function, reuptake sites, receptor availability, and drug efficacy.
• PET facilitates the study of L-dopa metabolism and its therapeutic effects in PD patients.